TacticScaleWhat Zai Lab Does & How It Makes Money (9688.HK)
Updated October 2026 · reflects Zai Lab's latest reported financials
China-based biopharma company commercializing licensed cancer, immunology and infection drugs. It earns revenue mainly from selling commercial drugs licensed through collaborations with global partners such as Tesaro, argenx, Novocure, Deciphera and Pfizer, while also investing in its own pipeline.
How Zai Lab makes money
It earns revenue mainly from selling commercial drugs licensed through collaborations with global partners such as Tesaro, argenx, Novocure, Deciphera and Pfizer, while also investing in its own pipeline.
What Zai Lab does
Zai Lab is a Shanghai (Pudong)-based biopharmaceutical company, founded in 2013, working across oncology, immunology, neuroscience and infectious diseases. Its commercial portfolio includes Zejula (a PARP inhibitor for ovarian cancer), VYVGART (for generalized myasthenia gravis and CIDP), Optune (tumor-treating device for glioblastoma), Qinlock (GIST), Augtyro (ROS1-positive non-small cell lung cancer), and the antibiotics NUZYRA and Xacduro. Most of these products come from collaborations with international partners, including Tesaro, NovoCure, Deciphera, Paratek, argenx, Turning Point, Entasis, Karuna, Pfizer, Amgen and Boehringer Ingelheim. That makes Zai Lab mainly a company that licenses in and commercializes drugs, alongside its own discovery and development work.
Products & services
- Zejula (niraparib)
- VYVGART (efgartigimod)
- Optune
- Qinlock
- NUZYRA
- Xacduro
- Augtyro
What is Zai Lab worth?
A reliable owner-earnings fair value isn't available for this company yet — we'd rather say so than print a number we don't trust.
We show a fair value only when the method is trustworthy. See Zai Lab on TacticScale →
Related companies
Suzhou Zelgen Biopharmaceuticals (688266.SS) · Dizal (Jiangsu) Pharmaceutical (688192.SS) · Livzon Pharmaceutical (000513.SZ)